Loading the session
Loading the session
Loading instrument
$381.00
+7.32%Market closedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:25 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
Closed at $377.78 on 4 Nov 2026: 2.8% below the 52-week high of $388.66 (21 Oct 2026) and 48.8% above the low of $253.95 (11 Jun 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
The 4 Nov 2026 gain of 6.4% was 3.8× its average daily move of 1.7% over the past year, and its largest one-day gain since 15 Oct 2026.
Daily closes, split-adjusted · as of 4 Nov 2026
1 month: +4.1% (SPY −1.6%, XLV +13.5%). 3 months: +15.3% (SPY −0.4%, XLV +15.5%). 1 year: +22.2% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ONC, SPY and XLV · as of 4 Nov 2026
The 4 Nov 2026 close of $377.78 was 4.2% above its 50-day average ($362.57) and 16.1% above its 200-day average ($325.33). It has closed above the 200-day for 66 sessions, since 4 Aug 2026. The 50-day average crossed above the 200-day on 25 Aug 2026, 50 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
4 Nov 2026 volume of 630.2K shares was 1.6× the average of the 30 sessions before it (384.7K), as the price rose 6.4%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes mainly with AbbVie and AstraZeneca. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
September 10, 2025
−10.59%April 22, 2025
+10.27%April 11, 2025
+10.59%